Post-earnings recap
Reported
Tue, Nov 12, 2024
EPS actual
$-0.96
EPS est.
$-0.91
EPS surprise
-5.84%
1-day move
-2.05%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Crinetics Pharmaceuticals reported a wider-than-expected loss per share, which contributed to a 2.05% decline in stock price following the earnings announcement. The lack of revenue details and future guidance may leave investors uncertain about the company's near-term performance. The management's focus on clinical trials suggests they are prioritizing long-term growth over immediate financial results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.96 | N/A | -5.84% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding the current market conditions. They emphasized their commitment to advancing clinical programs without offering specific financial guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on ongoing clinical trials and product development.